Abstract：
Low-grade serous ovarian cancer (LGSC) represents 5% of all epithelial ovarian cancers. They are characterized by indolent growth and KRAS and BRAF mutations, differing from high-grade serous ovarian cancer both clinically and molecularly. LGSC has low response rates to traditional systemic therapies, including chemotherapy and hormonal therapy. The objective of this systematic review was to appraise the literature describing the efficacy of MEK inhibitors in the treatment of LGSC.
A comprehensive search was conducted of the following databases: Medline ALL, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Web of Sciences, ClinicalTrials.gov, International Clinical Trials Registry Platform (ICFRP), and International Standard Randomized Controlled Trials Number (ISRCTN) Registry. All studies investigating MEKi in the treatment of LGSC in the adjuvant or recurrent setting for patients 18 years of age or older were included. All titles/abstracts were then screened by 2 independent reviewers (A.K. and C.C.). The full-text articles were then screened. All disagreements were resolved by a third independent reviewer (T.Z.). Two independent reviewers (A.K. and C.C.) extracted data from the studies deemed eligible for final review.
A total of 2108 studies were identified in the initial search. Of these, a total of 4 studies met the eligibility criteria for systematic review. In these studies, 416 patients were treated with an MEKi alone. All patients included in the studies were being treated for LGSC in the recurrent setting. Varied results and efficacy of the MEKi were reported in each study.
The results highlighted in this systematic review demonstrate varied responses to MEKi for recurrent LGSC. Further research is needed in this field comparing the efficacy to current therapies, as well as to further evaluate the safety and toxicity profile with long-term use of MEKi.
A comprehensive search was conducted of the following databases: Medline ALL, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Web of Sciences, ClinicalTrials.gov, International Clinical Trials Registry Platform (ICFRP), and International Standard Randomized Controlled Trials Number (ISRCTN) Registry. All studies investigating MEKi in the treatment of LGSC in the adjuvant or recurrent setting for patients 18 years of age or older were included. All titles/abstracts were then screened by 2 independent reviewers (A.K. and C.C.). The full-text articles were then screened. All disagreements were resolved by a third independent reviewer (T.Z.). Two independent reviewers (A.K. and C.C.) extracted data from the studies deemed eligible for final review.
A total of 2108 studies were identified in the initial search. Of these, a total of 4 studies met the eligibility criteria for systematic review. In these studies, 416 patients were treated with an MEKi alone. All patients included in the studies were being treated for LGSC in the recurrent setting. Varied results and efficacy of the MEKi were reported in each study.
The results highlighted in this systematic review demonstrate varied responses to MEKi for recurrent LGSC. Further research is needed in this field comparing the efficacy to current therapies, as well as to further evaluate the safety and toxicity profile with long-term use of MEKi.
摘要：
目的：低级别浆液性卵巢癌（LGSC）占所有上皮性卵巢癌的5％。它们的特征是惰性生长和KRAS和BRAF突变，在临床和分子上都不同于高级别浆液性卵巢癌。LGSC对传统系统疗法的反应率低，包括化疗和激素治疗.本系统综述的目的是评估描述MEK抑制剂治疗LGSC疗效的文献。
方法：对以下数据库进行了全面搜索：MedlineALL，EMBASE,Cochrane中央控制试验登记册,Cochrane系统评价数据库，WebofSciences,ClinicalTrials.gov,国际临床试验注册平台(ICFRP)和国际标准随机对照试验编号（ISRCTN）注册。包括所有研究MEKi在18岁或以上患者的辅助或复发环境中治疗LGSC的研究。然后由2名独立审稿人(A.K.和C.C.)筛选所有标题/摘要。然后对全文文章进行筛选。所有分歧均由第三位独立审查员（T.Z.）解决。两名独立审稿人（A.K.和C.C.）从被认为有资格进行最终审查的研究中提取数据。
结果：在初始搜索中确定了总共2108项研究。其中,共有4项研究符合系统评价的资格标准.在这些研究中,416例患者仅接受MEKi治疗。研究中包括的所有患者都在复发性环境中接受LGSC治疗。在每项研究中报告了MEKi的不同结果和功效。
结论：本系统评价中强调的结果表明，复发性LGSC对MEKi的反应各不相同。在这一领域需要进一步的研究，比较目前的治疗效果，以及进一步评估长期使用MEKi的安全性和毒性。
方法：对以下数据库进行了全面搜索：MedlineALL，EMBASE,Cochrane中央控制试验登记册,Cochrane系统评价数据库，WebofSciences,ClinicalTrials.gov,国际临床试验注册平台(ICFRP)和国际标准随机对照试验编号（ISRCTN）注册。包括所有研究MEKi在18岁或以上患者的辅助或复发环境中治疗LGSC的研究。然后由2名独立审稿人(A.K.和C.C.)筛选所有标题/摘要。然后对全文文章进行筛选。所有分歧均由第三位独立审查员（T.Z.）解决。两名独立审稿人（A.K.和C.C.）从被认为有资格进行最终审查的研究中提取数据。
结果：在初始搜索中确定了总共2108项研究。其中,共有4项研究符合系统评价的资格标准.在这些研究中,416例患者仅接受MEKi治疗。研究中包括的所有患者都在复发性环境中接受LGSC治疗。在每项研究中报告了MEKi的不同结果和功效。
结论：本系统评价中强调的结果表明，复发性LGSC对MEKi的反应各不相同。在这一领域需要进一步的研究，比较目前的治疗效果，以及进一步评估长期使用MEKi的安全性和毒性。
